Epidemiology, healthcare resource utilization and healthcare costs for spinal muscular atrophy in Alberta, Canada

References

• Chaytow H, Faller KME, Huang YT, et al. Spinal muscular atrophy: from approved therapies to future therapeutic targets for personalized medicine. Cell Rep Med. 2021;2(7):100346.
   PubMedGoogle Scholar
• Wirth B. Spinal muscular atrophy: in the challenge lies a solution. Trends Neurosci. 2021;44(4):306–322.
   PubMed Web of Science ®Google Scholar
• Lefebvre S, Bürglen L, Reboullet S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80(1):155–165.
   PubMed Web of Science ®Google Scholar
• Verhaart IEC, Robertson A, Wilson IJ, et al. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review. Orphanet J Rare Dis. 2017;12(1):124.
   PubMedGoogle Scholar
• Prior TW, Snyder PJ, Rink BD, et al. Newborn and carrier screening for spinal muscular atrophy. Am J Med Genet A. 2010;152A(7):1608–1616.
   PubMed Web of Science ®Google Scholar
• Verhaart IEC, Robertson A, Leary R, et al. A multi-source approach to determine SMA incidence and research ready population. J Neurol. 2017;264(7):1465–1473.
   PubMed Web of Science ®Google Scholar
• Wang CH, Finkel RS, Bertini ES, et al. Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol. 2007;22(8):1027–1049.
   PubMed Web of Science ®Google Scholar
• Palomino MA, Castiglioni C. Respiratory care in spinal muscular atrophy in the new therapeutic era. Rev Chil Pediatr. 2018;89(6):685–693.
   PubMed Web of Science ®Google Scholar
• Mercuri E, Finkel RS, Muntoni F, et al. Diagnosis and management of spinal muscular atrophy: Part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord. 2018;28(2):103–115.
   PubMed Web of Science ®Google Scholar
• Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377(18):1723–1732.
   PubMed Web of Science ®Google Scholar
• Zerres K, Rudnik-Schöneborn S, Forrest E, et al. A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients. J Neurol Sci. 1997;146(1):67–72.
   PubMed Web of Science ®Google Scholar
• MedlinePLUS genetics. Spinal Muscular Atrophy. 2020; [cited 2020 Sep 25]. Available from: https://ghr.nlm.nih.gov/condition/spinal-muscular-atrophy.
   Google Scholar
• Armstrong EP, Malone DC, Yeh WS, et al. The economic burden of spinal muscular atrophy. J Med Econ. 2016;19(8):822–826.
   PubMed Web of Science ®Google Scholar
• Klug C, Schreiber-Katz O, Thiele S, et al. Disease burden of spinal muscular atrophy in Germany. Orphanet J Rare Dis. 2016;11(1):58.
   PubMedGoogle Scholar
• Tan H, Gu T, Chen E, et al. Healthcare utilization, costs of care, and mortality among Patients with spinal muscular atrophy. J Health Econ Outcomes Res. 2019;6(3):185–195.
   PubMedGoogle Scholar
• Dangouloff T, Botty C, Beaudart C, et al. Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments. Orphanet J Rare Dis. 2021;16(1):47.
   PubMed Web of Science ®Google Scholar
• Landfeldt E, Pechmann A, McMillan HJ, et al. Costs of illness of spinal muscular atrophy: a systematic review. Appl Health Econ Health Policy. 2021;19(4):501–520.
   PubMed Web of Science ®Google Scholar
• Finkel RS, Mercuri E, Meyer OH, et al. Diagnosis and management of spinal muscular atrophy: Part 2: pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscul Disord. 2018;28(3):197–207.
   PubMed Web of Science ®Google Scholar
• Canadian agency for drugs and technologies in health. Nusinersen pharmacoeconomic review report. Ottawa, Ontario, Canada: Canadian Agency for Drugs and Technologies in Health; 2018.
   Google Scholar
• Health Canada. Regulatory Decision Summary – Zolgensma. 2020.
   Google Scholar
• Hoffman-La Roche. Roche presents new 2-year data for Evrysdi (risdiplam) in infants with Type 1 spinal muscular atrophy (SMA). 2020; [cited 2021 Jan 22]. Available from: https://www.roche.com/media/releases/med-cor-2020-09-28.htm.
   Google Scholar
• GBD 2016 Motor Neuron Disease Collaborators. Global, regional, and national burden of motor neuron diseases 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol. 2018;17(12):1083–1097.
   PubMed Web of Science ®Google Scholar
• Rose L, McKim D, Leasa D, et al. Trends in incidence, prevalence, and mortality of neuromuscular disease in Ontario, Canada: a population-based retrospective cohort study (2003–2014). PLoS One. 2019;14(3):e0210574.
   PubMed Web of Science ®Google Scholar
• Lefter S, Hardiman O, Ryan AM. A population-based epidemiologic study of adult neuromuscular disease in the Republic of Ireland. Neurology. 2017;88(3):304–313.
   PubMed Web of Science ®Google Scholar
• König K, Pechmann A, Thiele S, et al. De-duplicating patient records from three independent data sources reveals the incidence of rare neuromuscular disorders in Germany. Orphanet J Rare Dis. 2019;14(1):152.
   PubMedGoogle Scholar
• Husebye SA, Rebne CB, Stokland AE, et al. A hospital based epidemiological study of genetically determined muscle disease in south western Norway. Neuromuscul Disord. 2020;30(3):181–185.
   PubMed Web of Science ®Google Scholar
• Okamoto K, Fukuda M, Saito I, et al. Incidence of infantile spinal muscular atrophy on Shikoku Island of Japan. Brain Dev. 2019;41(1):36–42.
   PubMed Web of Science ®Google Scholar
• Vill K, Kölbel H, Schwartz O, et al. One year of newborn screening for SMA – results of a German pilot project. J Neuromuscul Dis. 2019;6(4):503–515.
   PubMedGoogle Scholar
• Draušnik Ž, Cerovečki I, Štefančić V, et al. The prevalence of muscular dystrophy and spinal muscular atrophy in Croatia: data from national and non-governmental organization registries. Croat Med J. 2019;60(6):488–493.
   PubMed Web of Science ®Google Scholar
• Statistics Canada. Table 17-10-0005-01. Population estimates on July 1st, by age and sex. Ottawa (Ontario): Statistics Canada.
   Google Scholar
• Gerstman BB. Epidemiology kept simple: an introduction to traditional and modern epidemiology. Oxford: John Wiley & Sons; 2013.
   Google Scholar
• Canadian Institute for Health Information. Health care cost drivers: the facts. Ottawa (Ontario): CIHI; 2011.
   Google Scholar
• Strategic Services Division Alberta Health. Health care cost drivers. Edmonton (Alberta): Alberta Health, 2013.
   Google Scholar
• Alberta Health. Continuing care accomodation charges. Alberta, Canada: Alberta Health, 2018; [cited 2021 Dec 04]. Available from: http://www.health.alberta.ca/services/continuing-care-accommodation-charges.html.
   Google Scholar
• Statistics Canada. Table 18-10-0005-01 Consumer Price Index, annual average, not seasonally adjusted. Ottawa (Canada): Statistics Canada. https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1810000501.
   Google Scholar
• Spronk I, Korevaar JC, Poos R, et al. Calculating incidence rates and prevalence proportions: not as simple as it seems. BMC Public Health. 2019;19(1):512.
   PubMedGoogle Scholar
• Zaldívar T, Montejo Y, Acevedo AM, et al. Evidence of reduced frequency of spinal muscular atrophy type I in the Cuban population. Neurology. 2005;65(4):636–638.
   PubMed Web of Science ®Google Scholar
• Glascock J, Sampson J, Haidet-Phillips A, et al. Treatment algorithm for infants diagnosed with spinal muscular atrophy through newborn screening. J Neuromuscul Dis. 2018;5(2):145–158.
   PubMedGoogle Scholar
• Lee M, Jr., França UL, Graham RJ, et al. Pre-Nusinersen hospitalization costs of children with spinal muscular atrophy. Pediatr Neurol. 2019;92:3–5.
   PubMed Web of Science ®Google Scholar
• Belter L, Cruz R, Kulas S, et al. Economic burden of spinal muscular atrophy: an analysis of claims data. J Mark Access Health Policy. 2020;8(1):1843277.
   PubMedGoogle Scholar
• Chambers GM, Settumba SN, Carey KA, et al. Prenusinersen economic and health-related quality of life burden of spinal muscular atrophy. Neurology. 2020;95(1):e1–e10.
   PubMed Web of Science ®Google Scholar
• Lopez-Bastida J, Pena-Longobardo LM, Aranda-Reneo I, et al. Social/economic costs and health-related quality of life in patients with spinal muscular atrophy (SMA) in Spain. Orphanet J Rare Dis. 2017;12(1):141.
   PubMedGoogle Scholar
• Darbà J, Marsà A. Patient characteristics and hospitalisation costs of spinal muscular atrophy in Spain: a retrospective multicentre database analysis. BMJ Open. 2019;9(11):e031271-e.
   Web of Science ®Google Scholar
• Peña-Longobardo LM, Aranda-Reneo I, Oliva-Moreno J, et al. The economic impact and Health-Related quality of life of spinal muscular atrophy: an analysis across Europe. Int J Enrivon Res Public Health. 2020;17(16):5640.
   Web of Science ®Google Scholar
• Cardenas J, Menier M, Heitzer MD, et al. High healthcare resource use in hospitalized patients with a diagnosis of spinal muscular atrophy type 1 (SMA1): retrospective analysis of the Kids' Inpatient Database (KID). Pharmacoecon Open. 2019;3(2):205–213.
   PubMed Web of Science ®Google Scholar
• Droege M, Sproule D, Arjunji R, et al. Economic burden of spinal muscular atrophy in the United States: a contemporary assessment. J Med Econ. 2020;23(1):70–79.
   PubMed Web of Science ®Google Scholar
• Canadian Institute for Health Information. National Health Expenditure Trends, 1975 to 2019. Canadian Agency for Drugs and Technologies in Health: CIHI, 2019.
   Google Scholar
• Farrar MA, Carey KA, Paguinto SG, et al. Financial, opportunity and psychosocial costs of spinal muscular atrophy: an exploratory qualitative analysis of Australian carer perspectives. BMJ Open. 2018;8(5):e020907.
   PubMed Web of Science ®Google Scholar
• McMillan HJ, Gerber B, Cowling T, et al. Burden of spinal muscular atrophy (SMA) on patients and caregivers in Canada. J Neuromuscul Dis. 2021;8(4):553–568.
   PubMedGoogle Scholar
• Alberta Health. Interactive drug benefit list: SPINRAZA 2.4 MG / ML Injection (Nusinersen Sodium). Edmonton (AB): Alberta Health; 2020.
   Google Scholar
• Zuluaga-Sanchez S, Teynor M, Knight C, et al. Cost effectiveness of nusinersen in the treatment of patients with Infantile-Onset and Later-Onset spinal muscular atrophy in Sweden. Pharmacoeconomics. 2019;37(6):845–865.
   PubMed Web of Science ®Google Scholar
• Lin CW, Kalb SJ, Yeh WS. Delay in diagnosis of spinal muscular atrophy: a systematic literature review. Pediatr Neurol. 2015;53(4):293–300.
   PubMed Web of Science ®Google Scholar